Shares of Exelixis, Inc. (NASDAQ:EXEL) ended Monday session in green amid volatile trading. The shares closed up +0.36 points or 2.20% at $16.76 with 7.90 million shares getting traded. Post opening the session at $16.40, the shares hit an intraday low of $16.01 and an intraday high of $17.00 and the price vacillated in this range throughout the day.
Market Cap/Outstanding Shares
The company has a market cap of $5.00 billion and the number of outstanding shares have been calculated to be 286.46 million shares.
Performance weekly/monthly/quarterly/yearly in percentage (%)
The performance for the week is valued at 35.60%, resulting in a performance for the month at 48.06%. Therefore, the stated figure displays a quarterly performance of 59.16% and an annual performance of 210.37%.traded up 2.20% on 14 November, 2016 hitting $16.76.
EPS (Earning Per Share )
The EPS of EXEL is strolling at -0.62, measuring its EPS growth this year at 41.30%. As a result, the company has an EPS growth of 95.70% for the approaching year. Company’s EPS for the past five years is valued at 0.90%.
Exelixis Inc. has a P/S value of 37.01, measuring P/B at 139.67. Its P/Cash is valued at 14.33 and P/FCF is at 16.62.
Beta factor is stands at 1.61 and Avg. true range is 0.91. Historically, the volatility of this stock is about 8.28% a week and 5.91% a month.
Exelixis, Inc. (EXEL) recently stated financial results for the third quarter of 2016 and offered an update on progress toward delivering upon its key 2016 corporate objectives, in addition to commercial and clinical development milestones.
Exelixis is focused on the U.S. launch of CABOMETYX™ (cabozantinib) tablets as a treatment for patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy. CABOMETYX generated $31.2 million in net product revenue during the third quarter of 2016, which reflects the first full quarter of product sales. Net product revenues for the third quarter of 2016, counting sales of COMETRIQ® (cabozantinib) capsules for the treatment of certain forms of thyroid cancer, were $42.7 million. While Exelixis focuses on commercialization in the United States, its partner Ipsen is in the process of launching CABOMETYX in the European Union, following the European Commission’s (EC) September 2016 approval of CABOMETYX for the treatment of adult patients with advanced RCC who have received prior vascular endothelial growth factor (VEGF)-targeted therapy. Exelixis is eligible to receive royalties on CABOMETYX sales by Ipsen outside of the United States, Canada and Japan.
“The third quarter of 2016 was an important inflection point for Exelixis. We recorded our first full quarter of CABOMETYX sales and also made noteworthyprogress on our path towards becoming a profitable, fully integrated, commercial biopharmaceutical company,” said Michael M. Morrissey, Ph.D., President and Chief Executive Officer of Exelixis. “Feedback from prescribers, in addition to performance to date, suggest that clinicians treating advanced renal cell carcinoma see CABOMETYX as a differentiated therapy and are increasingly incorporating it into their practice. While we continued to execute on the U.S. CABOMETYX launch and pursue important clinical trials like CABOSUN that have the potential to further advance our business, we also demonstrated sound fiscal discipline, resulting in a significantly reduced net loss and cash burn. As we close out the year, we remain committed to maximizing our opportunity to improve the treatment of cancer while building a strong and nimble company.”